Literature DB >> 24121274

HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.

C-H Tsai1, C-H Teng2, Y-T Tu2, T-S Cheng2, S-R Wu2, C-J Ko2, H-Y Shyu3, S-W Lan2, H-P Huang4, S-F Tzeng1, M D Johnson5, C-Y Lin5, P-W Hsiao1, M-S Lee2.   

Abstract

Dysregulation of cell surface proteolysis has been strongly implicated in tumorigenicity and metastasis. In this study, we delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) in prostate cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progression model (103E, N1, and N2 cells) and xenograft models. N1 and N2 cells were established through serial intraprostatic propagation of 103E human PCa cells and isolation of the metastatic cells from nearby lymph nodes. The invasion capability of these cells was revealed to gradually increase throughout the serial isolations (103E<N1<N2). In this series of cells, the expression of HAI-2 but not HAI-1 was significantly decreased throughout the progression and occurred in parallel with increased activation of matriptase. The expression level and activity of matriptase increased whereas the HAI-2 protein level decreased over the course of orthotopic tumor growth in mice, which was consistent with the immunohistochemical profiles of matriptase and HAI-2 in archival PCa specimens. Knockdown of matriptase reduced the PCa cell invasion induced by HAI-2 knockdown. HAI-2 overexpression or matriptase silencing in N2 cells downregulated matriptase activity and significantly decreased tumorigenicity and metastatic capability in orthotopically xenografted mice. These results suggest that during the progression of human PCa, matriptase activity is primarily controlled by HAI-2 expression. The imbalance between HAI-2 and matriptase expression led to matriptase activation, thereby increasing cell migration, invasion, tumorigenicity and metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24121274      PMCID: PMC4314694          DOI: 10.1038/onc.2013.412

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity.

Authors:  C Y Lin; J Anders; M Johnson; Q A Sang; R B Dickson
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

2.  Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor.

Authors:  T Kawaguchi; L Qin; T Shimomura; J Kondo; K Matsumoto; K Denda; N Kitamura
Journal:  J Biol Chem       Date:  1997-10-31       Impact factor: 5.157

3.  Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains.

Authors:  C W Marlor; K A Delaria; G Davis; D K Muller; J M Greve; P P Tamburini
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

4.  Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells.

Authors:  Ming-Shyue Lee; Ken-ichi Kiyomiya; Christelle Benaud; Robert B Dickson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2004-12-08       Impact factor: 4.249

5.  Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.

Authors:  Daniel Kirchhofer; Mark Peek; Michael T Lipari; Karen Billeci; Bin Fan; Paul Moran
Journal:  FEBS Lett       Date:  2005-03-28       Impact factor: 4.124

6.  Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.

Authors:  Mark R Morris; Dean Gentle; Mahera Abdulrahman; Esther N Maina; Kunal Gupta; Rosamonde E Banks; Michael S Wiesener; Takeshi Kishida; Masahiro Yao; Bin Teh; Farida Latif; Eamonn R Maher
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

7.  Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer.

Authors:  F Müller-Pillasch; C Wallrapp; K Bartels; G Varga; H Friess; M Büchler; G Adler; T M Gress
Journal:  Biochim Biophys Acta       Date:  1998-01-07

8.  Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.

Authors:  C Y Lin; J Anders; M Johnson; R B Dickson
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

9.  Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma.

Authors:  Kenichi Fukai; Osamu Yokosuka; Tetsuhiro Chiba; Yuichi Hirasawa; Motohisa Tada; Fumio Imazeki; Hiroaki Kataoka; Hiromitsu Saisho
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

10.  The hepatocyte growth factor regulatory factors in human breast cancer.

Authors:  Christian Parr; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

View more
  29 in total

1.  Loss of SPINT2 expression frequently occurs in glioma, leading to increased growth and invasion via MMP2.

Authors:  Márcia Santos Pereira; Sónia Pires Celeiro; Ângela Margarida Costa; Filipe Pinto; Sergey Popov; Gisele Caravina de Almeida; Júlia Amorim; Manuel Melo Pires; Célia Pinheiro; José Manuel Lopes; Mrinalini Honavar; Paulo Costa; José Pimentel; Chris Jones; Rui Manuel Reis; Marta Viana-Pereira
Journal:  Cell Oncol (Dordr)       Date:  2019-11-07       Impact factor: 6.730

2.  Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.

Authors:  Cheng-Fan Lee; Andrew Dang; Elizabeth Hernandez; Rey-Chen Pong; Benjamin Chen; Rajni Sonavane; Ganesh Raj; Payal Kapur; Hsin-Ying Lin; Shang-Ru Wu; Chun-Jung Ko; U-Ging Lo; Hsin-Yu Lee; Jer-Tsong Hsieh; Ming-Shyue Lee
Journal:  Oncogene       Date:  2019-05-31       Impact factor: 9.867

Review 3.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

4.  Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.

Authors:  C-J Ko; S-W Lan; Y-C Lu; T-S Cheng; P-F Lai; C-H Tsai; T-W Hsu; H-Y Lin; H-Y Shyu; S-R Wu; H-H Lin; P-W Hsiao; C-H Chen; H-P Huang; M-S Lee
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

Review 5.  Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression.

Authors:  Nisha R Pawar; Marguerite S Buzza; Toni M Antalis
Journal:  Cancer Res       Date:  2019-01-04       Impact factor: 12.701

6.  Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.

Authors:  Bryan J Fraser; Serap Beldar; Almagul Seitova; Ashley Hutchinson; Dhiraj Mannar; Yanjun Li; Daniel Kwon; Ruiyan Tan; Ryan P Wilson; Karoline Leopold; Sriram Subramaniam; Levon Halabelian; Cheryl H Arrowsmith; François Bénard
Journal:  Nat Chem Biol       Date:  2022-06-08       Impact factor: 16.174

7.  SPINT2 Deregulation in Prostate Carcinoma.

Authors:  Márcia Santos Pereira; Gisele Caravina de Almeida; Filipe Pinto; Marta Viana-Pereira; Rui Manuel Reis
Journal:  J Histochem Cytochem       Date:  2015-10-06       Impact factor: 2.479

8.  Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Authors:  Devon Pendlebury; Ruiying Wang; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Benjamin J Madden; Marat D Kazanov; Evette S Radisky
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

Review 9.  Cell surface-anchored serine proteases in cancer progression and metastasis.

Authors:  Carly E Martin; Karin List
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

Review 10.  Type II transmembrane serine proteases as potential targets for cancer therapy.

Authors:  Andrew S Murray; Fausto A Varela; Karin List
Journal:  Biol Chem       Date:  2016-09-01       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.